多聚免疫球蛋白受体促进肝细胞癌肿瘤生长
该研究描述多聚免疫球蛋白受体(pIgR)此前未被认识到的促癌功能:pIgR过表达与YES原癌基因1激活相关,并以免疫受体酪氨酸激活基序依赖方式激活Yes-DAP12-Syk-Rac1/CDC42-MEK/ERK级联,促进细胞转化和肿瘤生长;pIgR与磷酸化Yes联合可作为HBsAg阳性早期肝细胞癌患者的预后生物标志物,靶向MEK/ERK或Yes可能成为pIgR/p-Yes阳性肝细胞癌亚组的治疗选择。
要点
- pIgR过表达通过激活Yes及下游MEK/ERK级联促进肝细胞转化和肿瘤生长。
- pIgR与磷酸化Yes联合可作为HBsAg阳性早期肝细胞癌患者的预后生物标志物。
- 基于细胞系异种移植和患者来源异种移植结果,靶向MEK/ERK或Yes可能成为pIgR/p-Yes阳性肝细胞癌亚组的治疗选择。
核心结论
- 本研究揭示pIgR促进肿瘤恶性的分子机制,提示靶向该通路在肝细胞癌中的临床潜力,并为免疫球蛋白受体的促癌作用提供新认识。
研究设计与样本
- 基于癌细胞系异种移植和原发患者来源异种移植的实验研究。
主要发现
- pIgR过表达与YES原癌基因1、Src家族酪氨酸激酶(Yes)激活相关,且Yes激活为pIgR诱导的促癌生长所必需。
- pIgR以免疫受体酪氨酸激活基序依赖方式激活Yes-DAP12-Syk-Rac1/CDC42-MEK/ERK级联,促进细胞转化和肿瘤生长,尽管pIgR自身不含ITAM序列。
- pIgR与磷酸化Yes水平联合可作为HBsAg阳性和早期肝细胞癌患者的预后生物标志物。
- 基于癌细胞系异种移植和原发患者来源异种移植结果,药理学靶向MEK/ERK或Yes为pIgR/p-Yes阳性肝细胞癌患者亚组提供治疗选择。
临床怎么用
- 作者基于细胞系异种移植和患者来源异种移植结果认为,靶向MEK/ERK或Yes可能成为pIgR/p-Yes阳性肝细胞癌亚组的治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Deregulation of the immune system is believed to contribute to cancer malignancy, which has led to recent therapeutic breakthroughs facilitating antitumor immunity. In a malignant setting, immunoglobulin receptors, which are fundamental components of the human immune system, fulfill paradoxical roles in cancer pathogenesis. This study describes a previously unrecognized pro-oncogenic function of polymeric immunoglobulin receptor (pIgR) in the promotion of cell transformation and proliferation. Mechanistically, pIgR overexpression is associated with YES proto-oncogene 1, Src family tyrosine kinase (Yes) activation, which is required for pIgR-induced oncogenic growth. Specifically, pIgR activates the Yes-DNAX-activating protein of 12 kDa-spleen tyrosine kinase-Rac1/CDC42-MEK (extracellular signal-regulated kinase kinase)/ERK (extracellular signal-regulated kinase) cascade in an immunoreceptor tyrosine-based activating motif (ITAM)-dependent manner to promote cell transformation and tumor growth, although pIgR itself does not contain an ITAM sequence. Additionally, the combination of pIgR and phosphorylated Yes (p-Yes) levels serves as a prognostic biomarker for hepatitis B surface antigen-positive and early-stage hepatocellular carcinoma (HCC) patients. Moreover, pharmacological targeting of MEK/ERK or Yes represents a therapeutic option for the subgroup of patients with pIgR/p-Yes-positive HCC based on our results with both cancer cell-line-based xenografts and primary patient-derived xenografts. CONCLUSION: Our findings reveal the molecular mechanism by which pIgR promotes cancer malignancy, suggest the clinical potential of targeting this pathway in HCC, and provide new insight into the oncogenic role of immunoglobulin receptors. (Hepatology 2017;65:1948-1962).
引用
- Yue X, Ai J, Xu Y, et al. Polymeric immunoglobulin receptor promotes tumor growth in hepatocellular carcinoma. Hepatology. 2017. PMID: 28073159. doi:10.1002/hep.29036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。